Table 1.
Change in systemic therapy 1990–2011: stage I–III (n = 8292)
| 1990–1998 | 1999–2004 | 2005–2011 | p value | |
|---|---|---|---|---|
| N (%) | N (%) | N (%) | ||
| Adjuvant chemotherapy (n = 4426) | 1230 (52%) | 1271 (53%) | 1925 (55%) | 0.134 |
| Taxane therapy (n = 2130) | 171 (14%) | 622 (49%) | 1337 (70%) | < 0.001 |
| Neoadjuvant therapy: chemotherapy patients (n = 618) | 150 (12%) | 157 (12%) | 311 (16%) | 0.001 |
| Hormone therapy: HR+ positive patients (n = 5602) | 1317 (70%) | 1677 (83%) | 2608 (87%) | < 0.001 |
| Trastuzumab therapy: HER2 positive patients (n = 515) | – | 86 (29%) | 429 (90%) | < 0.001 |